European Surgery

, Volume 38, Issue 2, pp 107–111 | Cite as

Interdisciplinary management of colorectal cancer liver metastases

  • Th. Gruenberger
  • B. Gruenberger
  • A. Becherer
  • J. Kettenbach
  • K. Dieckmann
  • W. Schima
Main Topic
Received:
Accepted:

Summary

BACKGROUND: Various major advances in the treatment of colorectal cancer liver metastases have resulted in an increasing number of therapeutic options. The design of a multidisciplinary protocol is essential to define best treatment sequence for these patients. METHODS: Interdisciplinary groups have been established in most specialized institutions around the world changing concepts towards a neoadjuvant treatment cascade even in resectable liver disease. RESULTS: Treatment protocols of these groups have not yet established generally excepted guidelines but an increasing number of impressive results will help us to define best patients' care directives. CONCLUSIONS: Multidisciplinary treatment approaches have resulted in an increasing number of patients with colorectal cancer liver metastases becoming candidates for potentially curable disease management.

Keywords

Colorectal cancer liver metastases Interdisciplinary therapy Oncosurge Liver surgery Neoadjuvant chemotherapy 

Interdisziplinäres Management von kolorektalen Lebermetastasen

Zusammenfassung

GRUNDLAGEN: Verschiedenste Fortschritte in der Behandlung von kolorektalen Lebermetastasen haben zu einer steigenden Anzahl von therapeutischen Optionen geführt. Die Erstellung eines multidisziplinären Protokolls stellt einen wesentlichen Beitrag zur Evaluierung der besten Behandlung dar. METHODIK: Interdisziplinäre Gruppen haben sich in den meisten spezialisierten Zentren zusammengefunden, und man ist in vielen von ihnen zu einer Therapieabfolge unter Beginn mit neoadjuvanter Chemotherapie sogar in primär resektablen Patienten übergegangen. ERGEBNISSE: Behandlungsprotokolle dieser Gruppen haben bisher noch keine allgemein akzeptierten Leitlinien in der Behandlung von kolorektalen Lebermetastasen bewirkt, doch wird eine Vielzahl von beeindruckenden Ergebnissen uns helfen diese Richtlinien zu definieren. SCHLUSSFOLGERUNGEN: Multidisziplinäre Konzepte haben zu einer steigenden Anzahl von Patienten mit Lebermetastasen geführt, die wir heutzutage potentiell kurativ behandeln können.

Schlüsselwörter

Kolorektale Lebermetastasen Interdisziplinäre Therapie Oncosurge Leberchirurgie Neoadjuvante Chemotherapie 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Grothey A, Sargent D, Goldberg RM, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209–1214PubMedCrossRefGoogle Scholar
  2. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23–30PubMedCrossRefGoogle Scholar
  3. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229–237PubMedCrossRefGoogle Scholar
  4. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghemard O, Levi F, Bismuth H (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240: 644–657PubMedGoogle Scholar
  5. Gruenberger T, Schuell B, Puhalla H, Schwanzer E, Bodngbauer M, Laengle F, Kornek G, Scheithauer W (2004) Changes in liver surgery for colorectal cancer liver metastases under neoadjuvant treatment strategies. Eur Surg 36: 317–321CrossRefGoogle Scholar
  6. Imamura H, Seyama Y, Kokudo N, Maema A, Sugawara Y, Sano K, Takayama T, Makuuchi M (2003) One-thousand-and-fifty-six hepatectomies without mortality in 8 years. Arch Surg 138: 1198–1206PubMedCrossRefGoogle Scholar
  7. Kokudo N, Imamura H, Sugawara Y, Sakamoto Y, Yamamoto J, Seki M, Makuuchi M (2004) Surgery for multiple hepatic colorectal metastases. J Hepatobiliary Pancreat Surg 11: 84–91PubMedCrossRefGoogle Scholar
  8. Jaeck D, Bachellier P, Nakano H, Oussoultzoglou E, Weber JC, Wolf P, Greget M (2003) One or two-stage hepatectomy combined with portal vein embolization for initially nonresectable colorectal liver metastases. Am J Surg 185: 221–229PubMedCrossRefGoogle Scholar
  9. Abdalla E, Vauthey J, Ellis L, Ellis V, Pollock R, Broglio K, Hess K, Curley S (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239: 818–827PubMedCrossRefGoogle Scholar
  10. Onaitis M, Morse M, Hurwitz H, Cotton P, Tyler D, Clavien P, Clary B (2003) Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases. Ann Surg 237: 782–788PubMedCrossRefGoogle Scholar
  11. Schmiegel W (2004) S3-guidelines colorectal cancer 2004. Z Gastroenterol 42: 1129–1177PubMedCrossRefGoogle Scholar
  12. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342PubMedCrossRefGoogle Scholar
  13. Folprecht G, Kohne C (2004) The role of new agents in the treatment of colorectal cancer. Oncology 66: 1–17PubMedCrossRefGoogle Scholar
  14. Ruers TJM, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T, Corstens FHM, Oyen WJG (2002) Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 20: 388–395PubMedCrossRefGoogle Scholar
  15. Sojar V, Stanisavljevic D, Hribernik M, Fius T, Kreuh D, Velkavrh U (2004) Liver surgery planning in 3D virtual space. HPB 6 (Suppl 1): 179Google Scholar
  16. Elias D, Baton O, Sideris L, Matsuhisa T, Pocard M, Lasser P (2004) Local recurrences after intraoperative radiofrequency ablation of liver metastases: a comparative study with anatomic and wedge resections. Ann Surg Oncol 11: 500–505PubMedCrossRefGoogle Scholar
  17. Gruenberger T, Morris D (2002) Staged treatment of bilobar hepatic metastases from colorectal cancer. Eur J Surg 168: 516–518PubMedCrossRefGoogle Scholar
  18. Hemming A, Reed A, Howard R, Fujita S, Hochwald S, Caridi J, Hawkins I, Vauthey J (2003) Preoperative portal vein embolization for extended hepatectomy. Ann Surg 237: 686–693PubMedCrossRefGoogle Scholar
  19. Azoulay D, Castaing D, Smail A, Adam R, Cailliez V, Laurent A, Lemoine A, Bismuth H (2000) Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg 231: 480–486PubMedCrossRefGoogle Scholar
  20. Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H (2000) Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg 232: 777–785PubMedCrossRefGoogle Scholar
  21. Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber J, Bachellier P (2004) A two-stage hepatectmomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg 240: 1037–1051PubMedCrossRefGoogle Scholar
  22. Fernandez F, Drebin J, Linehan D, Dehdashti F, Siegel B, Strasberg S (2004) Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 240: 438–447PubMedGoogle Scholar
  23. Taieb J, Artru P, Paye F, Louvet C, Perez N, Andre T, Gayet B, Hebbar M, Goebel FM, Tournigand C, Parc R, de Gramont A (2005) Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J Clin Oncol 23: 502–509PubMedCrossRefGoogle Scholar
  24. Masi G, Allegrini G, Cupini S, Marcucci L, Cerri E, Brunetti I, Fontana E, Ricci S, Andreuccetti M, Falcone A (2004) First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucov-orin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol 15: 1766–1772PubMedCrossRefGoogle Scholar
  25. Di Stefano DR, de Baere T, Denys A, Hakime A, Gorin G, Gillet M, Saric J, Trillaud H, Petit P, Bartoli JM, Elias D, Delpero JR (2005) Preoperative percutaneous portal vein embolization: evaluation of adverse events in 188 patients. Radiology 234: 625–630PubMedGoogle Scholar
  26. Abitabile P, Hartl U, Maurer CA (2004) The local ablation with radiofrequency enables a safe and efficient treatment of small liver tumors. J Clin Oncol (Meeting Abstracts) 22: 3724Google Scholar
  27. Gruenberger T, Schuell B, Kornek G, Scheithauer W (2004) Neoadjuvant chemotherapy for resectable colorectal cancer liver metastases: Impact on magnitude of liver resection and survival. J Clin Oncol (Meeting Abstracts) 22: 3598Google Scholar
  28. Quenet F, Nordlinger B, Rivoire M, Delpero JR, Portier G, Mery-Mignard D, Magherini E, Payrard S, Ychou M (2004) Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial. J Clin Oncol (Meeting Abstracts) 22: 3613Google Scholar
  29. Tabernero JM, Van Cutsem E, Sastre J, Cervantes A, Van Laethem JL, Humblet Y, Soulie P, Corretge S, Mueser M, De Gramont A (2004) An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results. J Clin Oncol (Meeting Abstracts) 22: 3512Google Scholar
  30. Poston G, Haller D, Kahan J, Cornelis M, Mahyaoui S (2004) Individualizse the treatment of liver metastases from colorectal cancer using RAND appropriateness method: Oncosurge decision model. Results of a consensus detecting from the international taskforce group. J Clin Oncol (Meeting Abstracts) 22: 3595Google Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Th. Gruenberger
    • 1
  • B. Gruenberger
    • 2
  • A. Becherer
    • 3
  • J. Kettenbach
    • 4
  • K. Dieckmann
    • 5
  • W. Schima
    • 6
  1. 1.Hepatobiliary Service, Division of General Surgery, Department of SurgeryMedical University ViennaViennaAustria
  2. 2.Department of Internal Medicine, Division of OncologyMedical University ViennaViennaAustria
  3. 3.Department of Nuclear MedicineMedical University ViennaViennaAustria
  4. 4.Department of Interventional RadiologyMedical University ViennaViennaAustria
  5. 5.Department of Radiation OncologyMedical University ViennaViennaAustria
  6. 6.Department of RadiologyMedical University ViennaViennaAustria

Personalised recommendations